Pfizer Inc. (TSX:PFE)
Canada flag Canada · Delayed Price · Currency is CAD
12.83
+0.02 (0.16%)
Nov 16, 2026, 1:48 PM EST

Revenue

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Primary Care Revenue
25.95B26.82B30.14B
Specialty Care Revenue (Pre-FY2026 Reporting)
-17.55B16.65B
Oncology Revenue (Pre-FY2026 Reporting)
-16.83B15.61B
Global Biopharmaceuticals Business (Biopharma) Revenue
62.25B61.20B62.40B
Business Innovation (Pfizer CentreOne) Revenue
1.37B1.34B1.15B
Revenue (Other)
5.00M42.00M81.00M
Revenue (Total)
63.63B62.58B63.63B

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.31B37.08B38.69B
Developed Markets Revenue
16.73B16.19B16.06B
Emerging Markets Revenue
9.58B9.31B8.88B
Revenue (Other)
2.00M--
Revenue (Total)
63.63B62.58B63.63B

Revenue by Geography 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.31B37.08B38.69B
Revenue (Total)
63.63B62.58B63.63B

Revenue by Geography 3

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
United States Revenue
37.31B37.08B38.69B
International Revenue
26.32B25.50B24.94B
Revenue (Total)
63.63B62.58B63.63B

EBT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Global Pharmaceuticals Business (Biopharma) Earnings
28.88B29.34B27.97B
Other Business Activities Earnings
-7.71B-8.20B-7.21B

Key Performance Indicators

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016FY 2015FY 2014FY 2013FY 2012
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12
Comirnaty - Direct Sales and Alliance Revenue
3.57B4.37B5.35B
Eliquis - Direct Sales and Alliance Revenue
9.13B7.96B7.37B
Paxlovid Revenue
874.00M2.36B5.72B
Prevnar Family Revenue
6.30B6.49B6.41B
Nurtec ODT/Vydura Revenue
1.73B1.42B1.26B
Abrysvo Revenue
1.17B1.03B755.00M
Vyndaqel Family Revenue
6.83B6.38B5.45B
Xeljanz Revenue
968.00M1.09B1.17B
Ibrance Revenue
4.19B4.12B4.37B